Cargando…
Prospects for Anti-Biofilm Pharmaceuticals
This commentary highlights several avenues currently being pursued in research labs to the development of new anti-biofilm pharmaceuticals. There is a real need for alternative therapeutic modalities for treating the persistent infections that sometimes form on implanted medical devices or compromis...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588180/ https://www.ncbi.nlm.nih.gov/pubmed/26343685 http://dx.doi.org/10.3390/ph8030504 |
_version_ | 1782392580767481856 |
---|---|
author | Stewart, Philip S. |
author_facet | Stewart, Philip S. |
author_sort | Stewart, Philip S. |
collection | PubMed |
description | This commentary highlights several avenues currently being pursued in research labs to the development of new anti-biofilm pharmaceuticals. There is a real need for alternative therapeutic modalities for treating the persistent infections that sometimes form on implanted medical devices or compromised niches within the body. Strategies being researched include discovering new antimicrobial agents that kill microorganisms in biofilms more effectively than do existing antibiotics, designing drugs that block microbial adhesion or interfere with intercellular communication, developing chemistries to disperse biofilms, and combining agents with different mechanisms of action. Though the need is great, the pathway to commercialization of new drugs is steep. One possible streamlined approach to navigating the regulatory approval process is to repurpose old drugs, a strategy that a few groups have shown can yield agents with anti-biofilm properties. |
format | Online Article Text |
id | pubmed-4588180 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-45881802015-10-08 Prospects for Anti-Biofilm Pharmaceuticals Stewart, Philip S. Pharmaceuticals (Basel) Commentary This commentary highlights several avenues currently being pursued in research labs to the development of new anti-biofilm pharmaceuticals. There is a real need for alternative therapeutic modalities for treating the persistent infections that sometimes form on implanted medical devices or compromised niches within the body. Strategies being researched include discovering new antimicrobial agents that kill microorganisms in biofilms more effectively than do existing antibiotics, designing drugs that block microbial adhesion or interfere with intercellular communication, developing chemistries to disperse biofilms, and combining agents with different mechanisms of action. Though the need is great, the pathway to commercialization of new drugs is steep. One possible streamlined approach to navigating the regulatory approval process is to repurpose old drugs, a strategy that a few groups have shown can yield agents with anti-biofilm properties. MDPI 2015-08-27 /pmc/articles/PMC4588180/ /pubmed/26343685 http://dx.doi.org/10.3390/ph8030504 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Commentary Stewart, Philip S. Prospects for Anti-Biofilm Pharmaceuticals |
title | Prospects for Anti-Biofilm Pharmaceuticals |
title_full | Prospects for Anti-Biofilm Pharmaceuticals |
title_fullStr | Prospects for Anti-Biofilm Pharmaceuticals |
title_full_unstemmed | Prospects for Anti-Biofilm Pharmaceuticals |
title_short | Prospects for Anti-Biofilm Pharmaceuticals |
title_sort | prospects for anti-biofilm pharmaceuticals |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588180/ https://www.ncbi.nlm.nih.gov/pubmed/26343685 http://dx.doi.org/10.3390/ph8030504 |
work_keys_str_mv | AT stewartphilips prospectsforantibiofilmpharmaceuticals |